Abstract
We reported that long non-coding RNA ZFAS1 was upregulated in epithelial ovarian cancer tissues, and was negatively correlated to the overall survival rate of patients with epithelial ovarian cancer in this study. While depletion of ZFAS1 inhibited proliferation, migration, and development of chemoresistance, overexpression of ZFAS1 exhibited an even higher proliferation rate, migration activity, and chemoresistance in epithelial ovarian cancer cell lines. We further found miR-150-5p was a potential target of ZFAS1, which was downregulated in epithelial ovarian cancer tissue. MiR-150-5p subsequently inhibited expression of transcription factor Sp1, as evidence by luciferase assays. Inhibition of miR-150-5p rescued the suppressed proliferation and migration induced by depletion of ZFAS1 in epithelial ovarian cancer cells, at least in part. Taken together, our findings revealed a critical role of ZFAS1/miR-150-5p/Sp1 axis in promoting proliferation rate, migration activity, and development of chemoresistance in epithelial ovarian cancer. And ZFAS1/miR-150-5p may serve as novel markers and therapeutic targets of epithelial ovarian cancer.
Highlights
Epithelial ovarian cancer (EOC) is most common type of ovarian cancer
In order to assess the role of zinc finger antisense 1 (ZFAS1) in EOC oncogenesis, we first analyzed ZFAS1 expression levels in 66 EOC tissue specimens by Quantitative real-time PCR (qRT-PCR)
The value was normalized to 10 normal ovarian epithelial tissues as shown in Figure 1A, we found that the expression levels of ZFAS1 were significantly higher in EOC tissues (p
Summary
Epithelial ovarian cancer (EOC) is most common type of ovarian cancer. Ovarian cancer has the highest mortality rate of all gynecologic malignancy, accounting for 5–6% of cancer-related death in women. 21,550 women develop ovarian cancer annually in the United States [1]. Cytoreductive surgery followed by a combination of platinum- and taxane-based chemotherapy has been widely used as the standard treatment of advanced ovarian cancer, most cases developed chemoresistance, and eventually died from this disease [2]. Because the molecular pathology of ovarian cancer remains unclear, survival rates of patients largely depend on the stage of ovarian cancer at diagnosis. A better understanding on molecular pathology of ovarian cancer will facilitate development of early detection approaches and novel therapies for patients with ovarian cancer
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
